Remission: does it already exist in chronic rhinosinusitis with nasal polyposis?

被引:8
作者
Chan, Yvonne [1 ]
Thamboo, Andrew V. [2 ]
Han, Joseph K. [3 ]
Desrosiers, Martin [4 ]
机构
[1] Univ Toronto, St Michaels Hosp, Temerty Fac Med, Dept Otolaryngol Head & Neck Surg, 30 Bond St,Unit 8-163 CC North, Toronto, ON M5B 1W8, Canada
[2] Univ British Columbia, Dept Surg, Div Otolaryngol Head & Neck Surg, Vancouver, BC, Canada
[3] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA
[4] Ctr Hosp Univ Montreal, Div Otolaryngol Head & Neck Surg, Montreal, PQ, Canada
关键词
Chronic rhinosinusitis; Nasal polyposis; Endoscopic sinus surgery; Remission; Inflammatory bowel diseases; Asthma; Epithelium; Type; 2; inflammation;
D O I
10.1186/s40463-023-00657-2
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background Remission, defined as absence of symptoms and objective markers of disease, is emerging as the penultimate goal in the management of several chronic diseases. The concept of remission, well-established in Rheumatology as well as Gastroenterology, is currently emerging in Respiratory Medicine for asthma. It is interesting to consider whether the disease remission concept might successfully be applied to Otolaryngology-Head and Neck Surgery in the management of chronic rhinosinusitis with nasal polyposis (CRSwNP). Objective The purpose of this letter is to explore the evidence supporting the concept of remission under continued medical therapy in chronic rhinosinusitis with nasal polyposis. Methods The authors reviewed the literature and summarized studies in chronic rhinosinusitis with nasal polyposis evaluating for evidence of clinical, biochemical, and endoscopic remission.Results Findings of the studies revealed that endoscopic sinus surgery with continued medical therapy achieved remission in approximately 50% of all patients. CRSwNP patients after primary endoscopic sinus surgery were able to achieve remission in 72% of instances, however this drops to 42% for patients having revision sinus surgery. For CRSwNP patients with co-morbidities such as asthma and aspirin exacerbated respiratory disease, remission rate drops to 23% and 23.5%, respectively compared to non-asthmatic CRSwNP patients who present a remission rate under continued medical therapy of 60%. Conclusion Remission of symptoms and evidence of disease under medical therapy is indeed a concept achievable in patients with CRSwNP, as demonstrated by studies in the literature. Various co-morbidities, notably asthma, apparently influence rate of remission. Better defining this outcome through consensus-based definitions will allow for the development of strategies in CRSwNP care that can help affected patients attain complete relief from clinical, biochemical, and endoscopic markers of CRS with judicious use of medication and surgery. Future efforts will attempt to improve on these outcomes by achieving symptomatic and endoscopic control of disease following cessation of therapy, potentially paving the way towards clinical remission or a 'cure' in CRS.
引用
收藏
页数:3
相关论文
共 50 条
[31]   Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis [J].
Chen, Stephanie ;
Zhou, Anna ;
Emmanuel, Benjamin ;
Thomas, Kim ;
Guiang, Hannah .
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (11) :1897-1911
[32]   A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis [J].
Brown, W. Colby ;
Senior, Brent .
CURRENT ALLERGY AND ASTHMA REPORTS, 2020, 20 (06)
[33]   Current Evidence for Biologic Therapy in Chronic Rhinosinusitis with Nasal Polyposis [J].
Ramaswamy, Uma S. ;
Melder, Katie ;
Patel, Vijay A. ;
Lee, Stella E. .
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2021, 54 (04) :689-699
[34]   Role of Nasal Packing in Surgical Outcome for Chronic Rhinosinusitis With Polyposis [J].
Verim, Aysegul ;
Seneldir, Luftu ;
Naiboglu, Baris ;
Karaca, Cigdem Tepe ;
Kulekci, Semra ;
Toros, Sema Zer ;
Oysu, Cagatay .
LARYNGOSCOPE, 2014, 124 (07) :1529-1535
[35]   Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics? [J].
Klimek, F. ;
Foerster-Ruhrmann, U. ;
Hagemann, J. ;
Cuevas, M. ;
Groeger, M. ;
Klimek, L. .
HNO, 2024, 72 (07) :484-493
[36]   Surgical management of chronic rhinosinusitis and nasal polyposis: a review of the evidence [J].
Alexander G. Chiu ;
David W. Kennedy .
Current Allergy and Asthma Reports, 2004, 4 :486-489
[37]   Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis [J].
Jonstam, Karin ;
Swanson, Brian N. ;
Mannent, Leda P. ;
Cardell, Lars-Olaf ;
Tian, Nian ;
Wang, Ying ;
Zhang, Donghui ;
Fan, Chunpeng ;
Holtappels, Gabriele ;
Hamilton, Jennifer D. ;
Grabher, Annette ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Bachert, Claus .
ALLERGY, 2019, 74 (04) :743-752
[38]   Subepithelial inflammatory load and basement membrane thickening in refractory chronic rhinosinusitis with nasal polyposis: a histopathological study [J].
Bassiouni, Ahmed ;
Ou, Judy ;
Rajiv, Sukanya ;
Cantero, Daniel ;
Vreugde, Sarah ;
Wormald, Peter-John .
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY, 2016, 6 (03) :248-255
[39]   Does maxillary arch remodeling exist in nasal polyposis? [J].
Gunhan, Kivanc ;
Can, Fatma ;
Uz, Uzdan ;
Serter, Selim ;
Unlu, Halis .
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY, 2010, 24 (06) :428-432
[40]   Chronic Rhinosinusitis with Nasal Polyps and Asthma [J].
Laidlaw, Tanya M. ;
Mullol, Joaquim ;
Woessner, Katharine M. ;
Amin, Nikhil ;
Mannent, Leda P. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03) :1133-1141